Deutsche Bank AG Makes New $1.74 Million Investment in CeriBell, Inc. $CBLL

Key Points

• Deutsche Bank initiated a $1.74 million stake in CeriBell during the second quarter, acquiring 89,581 shares and owning approximately 0.24% of the company. Several other institutional investors also increased their positions.
• Analyst sentiment remains generally positive, with a consensus rating of “Moderate Buy” and an average price target of $22.40; BTIG and Canaccord recently raised their targets to $30 and $26, respectively.
• CeriBell reported quarterly revenue of $28.1 million, exceeding estimates, but its loss of $0.51 per share was wider than expected. Meanwhile, insiders sold approximately 382,067 shares worth $8.03 million over the past 90 days.

Deutsche Bank AG acquired a new stake in shares of CeriBell, Inc. (NASDAQ:CBLL - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 89,581 shares of the company's stock, valued at approximately $1,742,000. Deutsche Bank AG owned 0.24% of CeriBell as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd boosted its holdings in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company's stock worth $28,000 after purchasing an additional 1,231 shares during the period. Strs Ohio bought a new position in CeriBell during the 1st quarter valued at approximately $27,000. CWM LLC raised its position in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company's stock valued at $40,000 after purchasing an additional 1,697 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock worth $43,000 after buying an additional 1,801 shares during the period. Finally, Larson Financial Group LLC increased its stake in shares of CeriBell by 1,403.1% during the fourth quarter. Larson Financial Group LLC now owns 2,871 shares of the company's stock valued at $63,000 after buying an additional 2,680 shares during the period.

Insider Activity

In other news, Director William W. Burke sold 2,207 shares of the business's stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $19.84, for a total value of $43,786.88. Following the sale, the director directly owned 23,022 shares of the company's stock, valued at $456,756.48. The trade was a 8.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Scott Blumberg sold 33,512 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $25.03, for a total value of $838,805.36. Following the completion of the sale, the chief financial officer owned 148,121 shares in the company, valued at $3,707,468.63. The trade was a 18.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 382,067 shares of company stock valued at $8,025,866. 17.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CBLL. BTIG Research boosted their price objective on shares of CeriBell from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, August 18th. Canaccord Genuity Group raised their target price on shares of CeriBell from $25.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Barclays raised shares of CeriBell to a "neutral" rating in a research note on Tuesday, August 18th. Finally, Weiss Ratings upgraded shares of CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CeriBell currently has a consensus rating of "Moderate Buy" and an average target price of $22.40.

CeriBell Stock Performance

Shares of CBLL stock opened at $23.73 on Friday. The company's fifty day moving average price is $20.11 and its 200-day moving average price is $19.35. The stock has a market cap of $910.76 million, a PE ratio of -13.48 and a beta of 0.81. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $25.33.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The business had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. On average, equities analysts expect that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

CeriBell Company Profile

CeriBell Corp NASDAQ: CBLL is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source